Edition:
United States

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

7.97USD
16 Jul 2018
Change (% chg)

$-0.12 (-1.48%)
Prev Close
$8.09
Open
$8.10
Day's High
$8.10
Day's Low
$7.77
Volume
97,258
Avg. Vol
232,651
52-wk High
$13.30
52-wk Low
$5.02

Latest Key Developments (Source: Significant Developments)

Bellicum Pharmaceuticals Reports Q1 Loss Per Share Of $0.68
Tuesday, 8 May 2018 04:01pm EDT 

May 8 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON SHAREHOLDERS $0.68.Q1 EARNINGS PER SHARE VIEW $-0.69 -- THOMSON REUTERS I/B/E/S.QTRLY GRANT REVENUE $154,000 VERSUS $128,000.Q1 REVENUE VIEW $32860.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Bellicum Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Monday, 16 Apr 2018 04:42pm EDT 

April 16 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 7.00 MILLION COMMON SHARES.  Full Article

Bellicum Pharmaceuticals Reports Qtrly Loss Per Share $0.66
Tuesday, 13 Mar 2018 04:01pm EDT 

March 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017.‍REMAINS ON TRACK TO FILE EUROPEAN MARKETING AUTHORIZATION APPLICATIONS FOR BPX-501 AND RIMIDUCID IN 2019​.QTRLY LOSS PER SHARE $0.66‍​.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.  Full Article

Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501
Tuesday, 13 Mar 2018 07:00am EDT 

March 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501.BELLICUM PHARMA - WORKING WITH INVESTIGATORS & U.S. FDA TO DEVELOP PROTOCOL FOR POTENTIAL U.S. REGISTRATION STUDY IN PEDIATRIC PATIENTS.BELLICUM PHARMA - EXPECTS TO INITIATE POTENTIAL U.S. REGISTRATION STUDY IN PEDIATRIC PATIENTS BY END OF 2018.BELLICUM PHARMA - FROM BP-004 STUDY, CO REPORTED HIGH RATES OF DISEASE-FREE SURVIVAL & OVERALL SURVIVAL IN PEDIATRIC PATIENTS WITH PID.  Full Article

Bellicum Pharma Says Effective Feb 20, Board Approved Increase In Size Of Board To 8 Members
Friday, 23 Feb 2018 04:24pm EST 

Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMA SAYS EFFECTIVE FEB 20, BOARD APPROVED INCREASE IN SIZE OF BOARD TO 8 MEMBERS - SEC FILING.  Full Article

Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies
Friday, 23 Feb 2018 07:00am EST 

Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES.BELLICUM - RECEIVED NOTIFICATION FROM FDA OUTLINING CRITERIA REQUIRED FOR LIFTING CLINICAL HOLD ON U.S. STUDIES OF BPX-501.BELLICUM PHARMACEUTICALS INC - CLINICAL HOLD DOES NOT AFFECT COMPANY'S BP-004 REGISTRATION TRIAL IN EUROPE.BELLICUM - PLANS TO IMPLEMENT REVISIONS TO U.S. STUDY PROTOCOLS, ADDITION OF MORE COMPREHENSIVE MONITORING, MANAGEMENT OF NEUROTOXICITY FOR BPX-501.  Full Article

Bellicum reports qtrly earnings per share loss‍ $0.71​
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum reports third quarter 2017 financial results.Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bellicum Pharmaceuticals enters a cancer research grant contract with cancer prevention and research institute of Texas
Tuesday, 15 Aug 2017 04:46pm EDT 

Aug 15 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum Pharmaceuticals says ‍on Aug. 9, entered a cancer research grant contract with cancer prevention and research institute of Texas .Bellicum Pharmaceuticals- under agreement CPRIT awarded grant of about $16.9 million to bellicum to fund research of a cancer therapy involving BPX-501​.Bellicum Pharmaceuticals Inc - Bellicum and CPRIT will retain joint ownership over any intellectual property developed under agreement.Bellicum Pharmaceuticals Inc - agreement will expire on February 29, 2020.  Full Article

Bellicum Pharmaceuticals qtrly loss per share $0.74
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Bellicum Pharmaceuticals Inc :Bellicum pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Bellicum pharmaceuticals inc qtrly loss per share $0.74.Bellicum pharmaceuticals inc says enrollment in pivotal eu bp-004 trial remains on track for completion by end of 2017.Bellicum pharmaceuticals -expects to initiate observational trial in pediatric patients receiving transplants from matched unrelated donors without bpx-501 in q3.  Full Article

Bellicum Pharmaceuticals files for mixed shelf offering of upto $150 mln
Wednesday, 28 Jun 2017 05:26pm EDT 

June 28 (Reuters) - Bellicum Pharmaceuticals Inc -:Bellicum Pharmaceuticals Inc files for mixed shelf offering of upto $150 million - sec filing.  Full Article